ID   TF-1 BCR/ABL
AC   CVCL_J294
SY   TF-1 BCR-ABL
DR   BTO; BTO:0004761
DR   cancercelllines; CVCL_J294
DR   Wikidata; Q54972198
RX   PubMed=18829496;
CC   Population: Japanese.
CC   Sequence variation: Gene fusion; HGNC; 15868; ABHD12 + HGNC; 1537; CBFA2T3; Name(s)=CBFA2T3-ABHD12 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Pro (c.182A>C); ClinVar=VCV000280409; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*94 (c.752delT); ClinVar=VCV001759367; Zygosity=Unspecified (from parent cell line).
CC   Transfected with: HGNC; 76; ABL1 (BCR-ABL1 fusion).
CC   Transfected with: HGNC; 1014; BCR (BCR-ABL1 fusion).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C7152; Erythroleukemia
DI   ORDO; Orphanet_318; Acute erythroid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0559 ! TF-1
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 05-10-23; Version: 15
//
RX   PubMed=18829496; DOI=10.1158/1078-0432.CCR-08-0461;
RA   Okabe S., Tauchi T., Ohyashiki K.;
RT   "Characteristics of dasatinib- and imatinib-resistant chronic
RT   myelogenous leukemia cells.";
RL   Clin. Cancer Res. 14:6181-6186(2008).
//